What is Editas Medicine (EDIT)?
Editas Medicine is a biotechnology company focused on the development of genome editing technologies for therapeutic applications. The company utilizes CRISPR and other gene-editing platforms to create treatments aimed at correcting genetic disorders. Editas Medicine's research efforts target a range of diseases, including inherited retinal conditions and other genetic abnormalities. The company operates within the biopharmaceutical industry, advancing gene-editing approaches through preclinical and clinical development stages. Its work involves collaboration with academic institutions and industry partners to develop and commercialize gene-editing therapies. Editas Medicine contributes to the emerging field of genomic medicine by seeking to harness precise genetic modifications to address medical conditions at their source.
Editas Medicine Stock Price Today: Live Overview
The price today is shaped by market movements, as Editas Medicine trades at $2.37. It has seen a price range from $2.23 to $2.39 during the session, with a daily percent change of 0%.
FAQ: Editas Medicine (EDIT)
What is the current price of EDIT stock?
The current price is $2.37.
Does EDIT pay dividends?
Dividends are not paid by this company.
Does EDIT have a formal corporate presence or regional headquarters in the UAE?
Editas Medicine does not have an official presence or subsidiary in the UAE and operates via partners.
What is EDIT best known for?
Editas Medicine is most famous for its CRISPR gene editing therapies.
What assets are typically shown together with EDIT?
Commonly shown alongside EDIT: Viking Therapeutics, Inc., DiaMedica Therapeutics Inc., Axsome Therapeutics Inc
Latest shares articles



